Dr. Anđelo Beletić participated in ‘Vall d'Hebron Talks by VHIR‘

On May 15th, 2025, Dr. Anđelo Beletić from Genos Ltd. had the privilege of being invited by his host, Dr. Joaquin Seras Franzoso—Principal Investigator of the Clinical Biochemistry, Drug Delivery & Therapy (CB- DT) group at Fundació Hospital Universitari Vall d'Hebron – Institut de Recerca (VHIR)— to peak at the institution’s well-known ‘Vall d'Hebron Talks by VHIR‘ series (https://vhir.vallhebron.com/ca/societat/activitats/vall-dhebron-talks-vhir-deciphering-igg-glycome-sweet-pathway-molecular-fundamentals-translational-research).

His talk, titled ‘Deciphering the IgG Glycome – The ‘Sweet’ Pathway from Molecular Fundamentals to Translational Research‘ offered an engaging overview of the structural and biological importance of IgG glycans, complex carbohydrates attached to the IgG molecule through enzymatic glycosylation. Dr. Beletić outlined recent methodological advances in IgG glycome profiling and shared key findings from large population studies, disease-focused research, and clinical interventions. He spoke about how factors such as age, sex, genetics, epigenetics, and lifestyle can affect glycosylation patterns—and how these, in turn, are linked to various conditions including autoimmune diseases, chronic inflammation, infections, and cancer.

Furthermore, he shared growing evidence that both lifestyle interventions (like diet and exercise) and pharmacological treatments can modify the IgG glycome. He concluded by highlighting the potential of IgG glycome profiling as a promising tool in personalized medicine—offering more precise diagnostic capabilities and paving the way for targeted therapies.